356 related articles for article (PubMed ID: 33187148)
1. Trop2: Jack of All Trades, Master of None.
Lenárt S; Lenárt P; Šmarda J; Remšík J; Souček K; Beneš P
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33187148
[TBL] [Abstract][Full Text] [Related]
2. A literature review of the promising future of
Wen Y; Ouyang D; Zou Q; Chen Q; Luo N; He H; Anwar M; Yi W
Ann Transl Med; 2022 Dec; 10(24):1403. PubMed ID: 36660684
[TBL] [Abstract][Full Text] [Related]
3. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
Cortesi M; Zanoni M; Maltoni R; Ravaioli S; Tumedei MM; Pirini F; Bravaccini S
Expert Opin Ther Targets; 2022 Jul; 26(7):593-602. PubMed ID: 35962580
[TBL] [Abstract][Full Text] [Related]
4. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
Shen M; Liu S; Stoyanova T
Am J Clin Exp Urol; 2021; 9(1):73-87. PubMed ID: 33816696
[TBL] [Abstract][Full Text] [Related]
5. Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus.
Hoppe S; Meder L; Gebauer F; Ullrich RT; Zander T; Hillmer AM; Buettner R; Plum P; Puppe J; Malter W; Quaas A
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230712
[TBL] [Abstract][Full Text] [Related]
6. Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas.
Müller JH; Plage H; Elezkurtaj S; Mandelkow T; Huang Z; Lurati MCJ; Raedler JB; Debatin NF; Vettorazzi E; Samtleben H; Hofbauer S; Furlano K; Neymeyer J; Goranova I; Ralla B; Weinberger S; Horst D; Roßner F; Schallenberg S; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Lennartz M; Minner S; Simon R; Sauter G; Zecha H; Schlomm T; Bady E
Front Oncol; 2023; 13():1342367. PubMed ID: 38282671
[TBL] [Abstract][Full Text] [Related]
7. Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors.
Mertens RB; Makhoul EP; Li X; Dadmanesh F
Ann Diagn Pathol; 2024 Feb; 68():152226. PubMed ID: 37995412
[TBL] [Abstract][Full Text] [Related]
8. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.
Liu X; Deng J; Yuan Y; Chen W; Sun W; Wang Y; Huang H; Liang B; Ming T; Wen J; Huang B; Xing D
Pharmacol Ther; 2022 Nov; 239():108296. PubMed ID: 36208791
[TBL] [Abstract][Full Text] [Related]
9. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.
Jabbarzadeh Kaboli P; Shabani S; Sharma S; Partovi Nasr M; Yamaguchi H; Hung MC
Am J Cancer Res; 2022; 12(4):1671-1685. PubMed ID: 35530278
[TBL] [Abstract][Full Text] [Related]
10. TROP2 Expression in Sebaceous and Sweat Gland Carcinoma.
Ito T; Hashimoto H; Tanaka Y; Tanegashima K; Murata M; Ichiki T; Iwasaki T; Oda Y; Kaku-Ito Y
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160059
[TBL] [Abstract][Full Text] [Related]
11. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
Vidula N; Yau C; Rugo H
Breast Cancer Res Treat; 2022 Aug; 194(3):569-575. PubMed ID: 35789445
[TBL] [Abstract][Full Text] [Related]
12. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
13. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
[TBL] [Abstract][Full Text] [Related]
14. Trop2 Expression in Extramammary Paget's Disease and Normal Skin.
Ito T; Tanegashima K; Tanaka Y; Hashimoto H; Murata M; Oda Y; Kaku-Ito Y
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299325
[TBL] [Abstract][Full Text] [Related]
15. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
Coates JT; Sun S; Leshchiner I; Thimmiah N; Martin EE; McLoughlin D; Danysh BP; Slowik K; Jacobs RA; Rhrissorrakrai K; Utro F; Levovitz C; Denault E; Walmsley CS; Kambadakone A; Stone JR; Isakoff SJ; Parida L; Juric D; Getz G; Bardia A; Ellisen LW
Cancer Discov; 2021 Oct; 11(10):2436-2445. PubMed ID: 34404686
[TBL] [Abstract][Full Text] [Related]
16. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
[TBL] [Abstract][Full Text] [Related]
17. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon.
Ahmed Y; Berenguer-Pina JJ; Mahgoub T
Oncology; 2021; 99(10):673-680. PubMed ID: 34280931
[TBL] [Abstract][Full Text] [Related]
18. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
[TBL] [Abstract][Full Text] [Related]
19. Identification of TROP2 (TACSTD2), an EpCAM-like molecule, as a specific marker for TGF-β1-dependent human epidermal Langerhans cells.
Eisenwort G; Jurkin J; Yasmin N; Bauer T; Gesslbauer B; Strobl H
J Invest Dermatol; 2011 Oct; 131(10):2049-57. PubMed ID: 21677668
[TBL] [Abstract][Full Text] [Related]
20. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
